EUVIMEDEUVIMED entdecken
Open Access

Advances in Systemic Therapy for Unresectable Hepatocellular Carcinoma: Commentary on The Impact of the STRIDE Regimen in HIMALAYA Trial

Leenah Abdulgader, Abdullah Esmail

Oncology Research · 2026 · 34 (3) · 1-10

DOI: 10.32604/or.2026.069227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Research, 2026. Verfasst von Leenah Abdulgader und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Maryland Medical Center, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Unresectable hepatocellular carcinoma (HCC) remains a global challenge, with limited effective treatment options for advanced-stage disease. The HIMALAYA trial (phase III randomized study that evaluated the STRIDE regimen) introduced the Single Tremelimumab Regular Interval Durvalumab (STRIDE) regimen, an immunotherapy-based approach that achieved a median overall survival (OS) of 16.43 months compared to 13.77 months with sorafenib. While statistically significant, this ~2.7 months OS gain warrants scrutiny in light of STRIDE's increased immune-related toxicity and cost. This commentary evaluates STRIDE's impact within the broader landscape of first-line systemic therapy for unresectable HCC, alongside other regimens such as atezolizumab plus bevacizumab and nivolumab plus ipilimumab. We explore STRIDE's mechanism of action, safety profile, modest progression-free survival (PFS) improvement, and implementation challenges, incorporating insights from 2023-2025 research. In addition, we discussed its limitations in non-viral HCC and Child-Pugh B patients, the role of emerging biomarkers, and the potential of radiation to enhance immunotherapy efficacy. As a dual immune checkpoint inhibitor (ICI) strategy, STRIDE offers an important advance that may not only extend survival but also open the door to future curative approaches. However, optimizing its use will require refined patient selection and further investigation of synergistic combination therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsHumansAntibodies, Monoclonal, HumanizedSorafenibRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

HIMALAYA trialHepatocellular carcinoma (HCC)overall survivalsingle tremelimumab regular interval durvalumab (STRIDE) regimensystemic therapy

Substanzen

Antibodies, MonoclonaltremelimumabdurvalumabAntibodies, Monoclonal, HumanizedSorafenib

Autor:innen und Institutionen

  • Department of Surgery, University of Maryland Medical Center, Baltimore, MD, USA.
  • Section of GI Oncology, Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Houston, TX, USA.

Zitieren

APA

Abdulgader, L., & Esmail, A. (2026). Advances in Systemic Therapy for Unresectable Hepatocellular Carcinoma: Commentary on The Impact of the STRIDE Regimen in HIMALAYA Trial. Oncology Research, 34(3), 1-10. https://doi.org/10.32604/or.2026.069227

Vancouver

Abdulgader L, Esmail A. Advances in Systemic Therapy for Unresectable Hepatocellular Carcinoma: Commentary on The Impact of the STRIDE Regimen in HIMALAYA Trial. Oncology Research. 2026;34(3):1-10. doi:10.32604/or.2026.069227

BibTeX
@article{Abdulgader2026,
  author = {Abdulgader, Leenah and Esmail, Abdullah},
  title = {Advances in Systemic Therapy for Unresectable Hepatocellular Carcinoma: Commentary on The Impact of the STRIDE Regimen in HIMALAYA Trial},
  journal = {Oncology Research},
  year = {2026},
  volume = {34},
  number = {3},
  pages = {1--10},
  doi = {10.32604/or.2026.069227}
}
Kostenlos starten →